« Return to News | Clinical Intelligence

Merck pulls out of Portola collaboration

Tuesday, March 29, 2011 12:49 PM

Merck has returned global rights for the investigational clotbuster betrixaban to California-based Portola Pharmaceuticals, according to PharmaTimes.

Betrixaban is an oral Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation. In July 2009, Merck and Portola announced a collaboration for the drug that could have been worth $470 million plus royalties, and Merck made an upfront payment of $50 million.

Betrixaban completed the phase II EXPLORE-Xa trial in which it showed dose-dependent clinical activity with similar or lower rates of bleeding compared to warfarin. Luciano Rossetti, head of global scientific strategy at Merck, said, "working closely with our Portola collaborators we have advanced betrixaban to this phase III-ready stage."

However, the rights have been returned "as part of an ongoing prioritization of our late-stage pipeline," though he stressed that Merck "remains committed to delivering medicines for cardiovascular disease."

Portola CEO William Lis said regaining the rights "represents a transformational opportunity" for the firm. "We will work with our academic partners on options for an independent development plan to bring betrixaban to the market and intend to discuss these options with the FDA in the near future."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.